Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to R-CHOP for newly diagnosed MYC-positive DLBCL or B-cell lymphoma, unclassifiable
NL-OMON24704Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma, sponsored by HOVON. Primary endpoint: Complete remission rate. Started Apr 2015; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON24704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24704.